why choose us

Clinical Trials Search

Showing 14,060 of 132,963 result(s)
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Status: Completed

Condition: Central Nervous System Neoplasms

Interventions: Autologous T cells transduced with a lentiviral vector expressing a B7-H3-CAR with a CD28z signaling domain and 41BB ligand (B7-H3-CAR T cells).

Date: 2023-03-23

A Study of Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures

Status: Completed

Condition: Bladder Spasms

Interventions: Intravenous infusion, load 50 mg;Kg with infusion of 15 mg;Kg;hour

Date: 2023-03-23

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

Status: Completed

Condition: Colon Cancer

Interventions: Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to a

Date: 2023-03-23

Oncology Care at Home for BMT and CAR-T

Status: ACTIVE_NOT_RECRUITING

Condition: Leukemia

Interventions: This study uses the BioIntelliSense BioButton Rechargeable for RPM, in combination with the BioSync mobile app on participants' mobile phones for

Date: 2023-03-23

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

Status: NOT_YET_RECRUITING

Condition: Systemic Lupus Erythematosus

Interventions: Hydroxychloroquine 200mg capsules.
Administered orally.

Date: 2023-03-23

Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead

Status: Completed

Condition: Overactive Bladder

Interventions: Removal of PNE lead at home

Date: 2023-03-23

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Status: NOT_YET_RECRUITING

Condition: Angiosarcoma

Interventions: Given by IV (vein)

Date: 2023-03-23

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

Status: Completed

Condition: Cerebral Adrenoleukodystrophy (cALD)

Interventions: Leriglitazone at a strength of 15 mg;ml.
Once-daily dosing at an initial volume of 10 ml

Date: 2023-03-23

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

Status: COMPLETED

Condition: IPF

Interventions: HNC1058 Capsules;Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg?HNC1058 Capsules;Placebos, 50 mg, single dose, FED

Date: 2023-03-23

First in Human Study of TLC-ART 101 (ACTU 2001)

Status: Completed

Condition: Human Immunodeficiency Virus

Interventions: TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension

Date: 2023-03-23